UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER
kmUU300MXic
kmUU300MXic
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Presentations<br />
Genes Versus T-Cells<br />
Authors*: Chloe Evelyn Atreya<br />
Abstract #:<br />
Presentation Date/Time: Saturday, June 4: 1:51-2:03 PM<br />
Location: Hall D1<br />
Poster Discussion Session: Gastrointestinal (Colorectal) Cancer<br />
Citation:<br />
Atreya Research Interests: Dr. Atreya specializes in gastrointestinal cancer, particularly colorectal cancer. Her<br />
research focuses on the interplay of tumor genetics and response to therapies for colorectal cancer, with the<br />
goal of improving patient outcomes and quality of life by personalizing treatment. Dr. Atreya is the recipient<br />
of numerous awards, including the Conquer Cancer Foundation of the American Society of Clinical Oncology<br />
Young Investigator Award and Alliance for Clinical Trials in Oncology Foundation Investigator Award. She<br />
is the recipient of a National Cancer Institute/National Institutes of Health K08 Career Development Award<br />
for Targeting of Aberrant Signaling in Patient-Derived Colorectal Cancer Models. Dr. Atreya is a member of<br />
the American Society of Clinical Oncologists, American Association of Cancer Researchers and Alliance for<br />
Clinical Trials in Oncology, Gastrointestinal Committee.<br />
http://cancer.ucsf.edu/gi/chloe-atreya<br />
__________________________________________________________________________<br />
Developing a Road Map to Guide Immunotherapy<br />
Authors*: Lawrence Fong<br />
Abstract #:<br />
Presentation Date/Time: Saturday, June 4: 2:51 - 3:03 PM<br />
Location: Hall B1<br />
Oral Abstract Session: Developmental Therapeutics - Immunotherapy<br />
Citation:<br />
Fong Research Interests: My lab focuses on how the immune system interacts with cancer as well as exploring<br />
tumor immunotherapies in mouse models and in patients. Our primary focus is in cancer immunotherapy.<br />
We investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can<br />
enhance anti-tumor immunity both systemically and in the tumor microenvironment. Performing neoadjuvant<br />
immunotherapy trials, we determine how specific therapies can recruit immune effectors in cancer patients.<br />
Moreover, we have studied how clinical responders may differ from clinical non-responders. We are applying<br />
unbiased approaches to studying antigen-specific responses that are modulated in these patients and are<br />
currently developing biomarkers that may be redictive of clinical efficacy.<br />
http://hemonc.ucsf.edu/fonglab/<br />
*<strong>UCSF</strong> authors in bold<br />
38
Change language